Literature DB >> 20144130

Esophagitis caused by Candida guilliermondii in diabetes mellitus: first reported case.

Danielle P C Macêdo1, Neiva T Oliveira, Aline M A Farias, Vanessa K A Silva, Ana B Wilheim, Fabíola M Couto, Rejane P Neves.   

Abstract

Diabetic patients are at risk of acquiring esophageal infections such as those caused by members of the genus Candida. Here we describe a case in which Candida guilliermondii was isolated from the esophageal mucosa of a patient with uncontrolled diabetes mellitus. Due to inappropriate and inaccurate identification, the emergence of non-C. albicans Candida species as potential pathogens has been underestimated. This should be a cause of concern since C. guilliermondii is a normal component of human microbiota. The identity of the isolate in our case was confirmed by its characteristic morphophysiological features and amplification of rDNA using species-specific primers. Fluconazole therapy produced no improvement of the esophageal symptoms, and resistance of the etiologic agent was confirmed through in vitro susceptibility tests. This is thought to be the first documented case of C. guilliermondii esophagitis in a patient with diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20144130     DOI: 10.3109/13693780903582614

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  2 in total

1.  Trichosporon inkin Esophagitis: An Uncommon Disease in a Patient with Pulmonary Cancer.

Authors:  Danielle Patrícia Cerqueira Macêdo; Neiva Tinti de Oliveira; Vanessa Karina Alves da Silva; Aline Mary de Almeida Farias; Reginaldo Gonçalves de Lima Neto; Ana Botler Wilheim; Patrícia Cariolano de Oliveira; Nadyr Pedi; Suanni Lemos de Andrade; Rejane Pereira Neves
Journal:  Mycopathologia       Date:  2010-09-23       Impact factor: 2.574

2.  PPARγ ligands switched high fat diet-induced macrophage M2b polarization toward M2a thereby improving intestinal Candida elimination.

Authors:  Lise Lefèvre; Amandine Galès; David Olagnier; José Bernad; Laurence Perez; Rémy Burcelin; Alexis Valentin; Johan Auwerx; Bernard Pipy; Agnès Coste
Journal:  PLoS One       Date:  2010-09-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.